Life Experience Matters: Enrichment and Stress Can Influence the Likelihood of Developing Alzheimer's Disease via Gut Microbiome
- PMID: 37509523
- PMCID: PMC10377385
- DOI: 10.3390/biomedicines11071884
Life Experience Matters: Enrichment and Stress Can Influence the Likelihood of Developing Alzheimer's Disease via Gut Microbiome
Abstract
Alzheimer's disease (AD) is a chronic neurodegenerative disease, characterized by the presence of β-amyloid (Aβ) plaques and neurofibrillary tangles (NFTs) formed from abnormally phosphorylated tau proteins (ptau). To date, there is no cure for AD. Earlier therapeutic efforts have focused on the clinical stages of AD. Despite paramount efforts and costs, pharmaceutical interventions including antibody therapies targeting Aβ have largely failed. This highlights the need to alternate treatment strategies and a shift of focus to early pre-clinical stages. Approximately 25-40% of AD cases can be attributed to environmental factors including chronic stress. Gut dysbiosis has been associated with stress and the pathogenesis of AD and can increase both Aβ and NFTs in animal models of the disease. Both stress and enrichment have been shown to alter AD progression and gut health. Targeting stress-induced gut dysbiosis through probiotic supplementation could provide a promising intervention to delay disease progression. In this review, we discuss the effects of stress, enrichment, and gut dysbiosis in AD models and the promising evidence from probiotic intervention studies.
Keywords: Alzheimer’s disease; chronic mild stress; enrichment; environmental factors; gut dysbiosis; gut microbiome; probiotics; stress.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease.Life Sci. 2021 Jan 1;264:118627. doi: 10.1016/j.lfs.2020.118627. Epub 2020 Oct 22. Life Sci. 2021. PMID: 33169684 Review.
-
Probiotic supplement as a promising strategy in early tau pathology prevention: Focusing on GSK-3β?Front Neurosci. 2023 Mar 22;17:1159314. doi: 10.3389/fnins.2023.1159314. eCollection 2023. Front Neurosci. 2023. PMID: 37034173 Free PMC article. Review.
-
Gut Microbiota Composition and Epigenetic Molecular Changes Connected to the Pathogenesis of Alzheimer's Disease.J Mol Neurosci. 2021 Jul;71(7):1436-1455. doi: 10.1007/s12031-021-01829-3. Epub 2021 Apr 8. J Mol Neurosci. 2021. PMID: 33829390 Review.
-
Target Dysbiosis of Gut Microbes as a Future Therapeutic Manipulation in Alzheimer's Disease.Front Aging Neurosci. 2020 Oct 6;12:544235. doi: 10.3389/fnagi.2020.544235. eCollection 2020. Front Aging Neurosci. 2020. PMID: 33132894 Free PMC article. Review.
-
Epigallocatechin-3-Gallate and Genistein for Decreasing Gut Dysbiosis, Inhibiting Inflammasomes, and Aiding Autophagy in Alzheimer's Disease.Brain Sci. 2024 Jan 19;14(1):96. doi: 10.3390/brainsci14010096. Brain Sci. 2024. PMID: 38275516 Free PMC article. Review.
References
-
- Alzheimer’s Association What Is Alzheimer’s Disease? Alzheimer’s Disease and Dementia. 2023. [(accessed on 2 March 2023)]. Available online: https://www.alz.org/alzheimers-dementia/what-is-alzheimers.
-
- Alzheimer Society of Canada What Is Alzheimer’s disease? Alzheimer Society of Canada. 2023. [(accessed on 2 March 2023)]. Available online: https://alzheimer.ca/en/about-dementia/what-alzheimers-disease.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources